BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Pro-Control-1000(TM) Line Poised to Help Manufacturers Improve Profits, Yields

Astrotech (NASDAQ: ASTC ), an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world, continues to expand its technology into new markets. “Astrotech has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly owned subsidiary, Pro-Control, Inc., that has been awarded an exclusive ATi field-of-use license for worldwide chemical manufacturing and process control applications. The Pro-Control-1000(TM) mass-spec is ideally suited for use in the chemical manufacturing industry due to its rugged design and highly reliable chemical analysis. The Pro-Control-1000(TM) is easy to operate with daily auto-calibration and auto-tune,” a recent article reads. “The company is very excited to be introducing our new Pro-Control, Inc. subsidiary along with the very capable Pro-Control-1000(TM) family of rugged mass-spectrometers. The ideal Pro-Control customer is a large-volume manufacturer of chemical products seeking to improve bottom-line profits. We believe that Pro-Control MVP can routinely improve manufacturing yields from 10% to 30%, and we are excited to introduce our technology to the vast chemical manufacturing market.”

To view the full article, visit https://ibn.fm/CE3BI

About Astrotech

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN